Article Text

Download PDFPDF
08.40 Evaluation of structural damage evolution in rheumatoid arthritis (ra) with optimisedoptimized doses of biological therapies (bt)
  1. Julia Uceda Montañez,
  2. Raquel Hernández Sánchez,
  3. L Marenco de la Fuente Jose
  1. Rheumatology Unit, University Valme Hospital, Seville. Spain


Background RA is the most common chronic inflammatory arthropathy. About 30% of patients are treated with BT. The optimisation of BT doses in patients in clinical remission of the disease is a strategy used in clinical practice. The best method for assessing structural damage in daily clinical practice is the SENS method (simplified form of the Van der Heijde method).

The main endpoint was evaluate the evolution of the structural damage of the disease in a cohort of patients with RA in follow-up in Rheumatology Unit, of Valme University Hospital, receiving optimised doses of BT, according to the BT dose optimisation protocol elaborated in our unity.

Materials and methods Observational, descriptive, longitudinal and retrospective study in a cohort of 32 patients diagnosed with RA (ACR 1987), who are treated at reduced doses of TB.

A description of the baseline characteristics was made.

The evolution of structural damage was measured using the SENS method on hand radiographs. The evaluation was done at different moments of the evolution: before the reduction, at the end of the reduction and in the current visit of collection of results.

Result 62.5% are women, mean age at diagnosis of 42.6 years. The duration of RA at the start of BT was 98.63 months and the biological treatment time at the beginning of the optimisation was 160.66 months

The 75% of the sample was FR positive and 56.7% ACPA positive. The 59.4% were with etanercept.

The mean of SENS score in hands before the optimisation was 8.78. The mean of SENS score in patients who continued optimised at time of analysis was 10.67. There were no statistically significant differences.

Conclusions All the patients in our study were in clinical remission of the disease at the beginning of the dose reduction of TB.

The results of our study suggest that optimised doses of BT in patients in clinical remission maintains the patient without significant progression of structural damage.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.